NCT02260531View on ClinicalTrials.gov

Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases

PHASE2CompletedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

January 4, 2019

Study Completion Date

March 17, 2020

Conditions

Breast CancerBrain Tumor - Metastatic

Interventions

DRUG

Cabozantinib

DRUG

Trastuzumab

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (2)

Genentech, Inc.

All Listed Sponsors

collaborator

Exelixis

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER